20/20 Biolabs, Inc. key statistics and ratios

In fiscal 2025, 20/20 Biolabs, Inc. had an operating margin of -162.9% and a current ratio of 0.60. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

20/20 Biolabs, Inc.: financial ratios, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Gross margin	20.6%	29.6%
Operating margin	−324.0%	−162.9%
Net margin	−316.8%	−182.8%
Return on assets	−154.9%	−96.8%
Asset turnover	0.49	0.53
Current ratio	1.50	0.60
Debt to equity	0.0%	—
Interest cover (operating income ÷ interest)	n/m	n/m
R&D as % of revenue	72.0%	29.0%
SG&A as % of revenue	271.6%	163.5%

US$ thousands unless shown otherwise. Fiscal quarters.

20/20 Biolabs, Inc.: financial ratios, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	29.9%	30.5%	17.8%	41.7%
Operating margin	−139.4%	−158.1%	−408.4%	−170.3%
Net margin	−138.1%	−157.2%	−615.4%	−206.2%
Current ratio	—	—	1.82	1.99
R&D as % of revenue	24.7%	36.3%	43.4%	35.3%
SG&A as % of revenue	144.7%	152.3%	382.8%	176.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026

What it owns · $6m

Short-term assets $5mLonger-term assets $1m

What it owes, and who funded it · $5m

Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $2m

Short-term assets cover short-term liabilities $5m of assets due within a year against $3m of liabilities due within a year.
Short-term assets cover long-term liabilities $5m short-term assets against $412,641 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From 20/20 Biolabs, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 20/20 Biolabs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 20/20 Biolabs, Inc.